论文部分内容阅读
根据中国药学会北京分会主持召开的双呋啶、呋喃氟脲嘧啶临床再评价会(于1984年5月24日召开)的资料,作一简述。双呋啶(FD-1),国外于1976年合成,1977年试用于临床。在我国,济南制药厂于1980年合成此药。FD-1为抗代谢药5-氟脲嘧啶(5-Fu)的衍生物,其作用机制系在体内干扰阻断脱氧核糖核酸、核糖核酸及蛋白质的合成。有资料报道,FD-1的化疗指数为5-Fu的4倍,毒副作用为5-Fu的1/8,毒性较低。据
According to the Beijing Branch of the Chinese Pharmaceutical Association under the auspices of the dual furo-furan fluorouracil clinical reevaluation meeting (held on May 24, 1984) for a brief overview. The double furfuridine (FD-1), synthesized in 1976 abroad, in 1977 trial for clinical. In our country, Jinan Pharmaceutical Factory synthesized this medicine in 1980. FD-1 is a derivative of 5-fluorouracil (5-Fu), an antimetabolite drug whose mechanism of action is to interfere with the synthesis of DNA, RNA and protein in vivo. Data have been reported, FD-1 chemotherapy index 4-fold 5-Fu, toxic side effects of 5-Fu 1/8, lower toxicity. according to